Breaking News

Transgenomic, Amgen in Cancer Detection Pact

May 6, 2013

Will develop test to screen for mCRC

Transgenomic, Inc. has entered into a collaboration with Amgen to develop a CE-IVD test to screen patients with metastatic colorectal cancer (mCRC) for RAS mutations (KRAS and NRAS). These RAS mutations are identified with CE-IVD CRC RAScan kits using Surveyor-Wave technology, and provide physicians with important information regarding tumor mutation status. Financial terms were not disclosed.
 
“This collaboration with Amgen is indicative of how Transgenomic’s proprietary molecular technologies are advancing personalized medicine,” said Craig Tuttle, chief executive officer of Transgenomic. “This highly precise, innovative test was developed at Transgenomic’s laboratories, which excel in genomic and genetic analysis, novel technology development, and its application in clinical research and trials.”

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016